The Acromegaly Drug Market is expected to register a CAGR of 7.2% during the forecast period. Acromegaly is a hormonal condition that occurs when the pituitary gland produces too much growth hormone in maturity.

Bones develop in size, when you have too much growth hormone. This causes gigantism in children, which is defined as an increase in height. In adulthood, however, there is no variation in height. Instead, acromegaly refers to an increase in bone size that is limited to the bones of your hands, foot, and face. Hypertension, osteoarthritis, diabetes mellitus, goitre, and eyesight loss are some of the problems associated with acromegaly progression.

Free Sample Copy @ https://www.omrglobal.com/request-sample/acromegaly-drugs-market

Acromegaly affects around 69,000 people globally and about 24,000 in the US, of whom an estimated 8,000 are treated chronically with somatostatin analogue injections. According to the National Institutes of Health (NIH), there are three to four new cases per million each year.

The rising Global Knowledge about hormonal problem, medication and therapies drives the market during the forecast period.

The improvement in the patient's overall clinical status as a result of the treatment is a significant contributor to the market's growth.

A Full Report of Global Acromegaly Drugs Market is Available at:
https://www.omrglobal.com/industry-reports/acromegaly-drugs-market

An increase in the number of patients with this rare disease, particularly among the adult population, enhances demand for the drug, which is expected to fuel market expansion significantly during the forecast years.

Technological advancements and increased R&D expenditure from major manufacturers, in discovery of innovative goods are giving profitable chances, that will fuel market growth over the forecast years.

In March 2021, the US Food and Drug Administration (FDA) approved MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Global Acromegaly Drugs Market – Segmentation
by Product Type
Somatostatin Analogs
Growth Hormone Receptor Antagonist (GHRA)
Dopamine Agonists
Other Product Types
by application
Hospital
Pharmacy

Global Acromegaly Drugs Market – Segmentation by Region 
North America 
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific 
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Company Profiles
Pfizer Inc
Novartis AG
Validus Pharmaceuticals LLC
Ipsen
Chiasma Inc
Ionis Pharmaceuticals Inc.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/acromegaly-drugs-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404